- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
- Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 948
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 57 more
- Conditions
- Melanoma (Skin)
- Interventions
- interleukin-2, filgrastim, interferon alfa, cisplatin, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 296
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 197 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 816
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 512 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Placebo, KBP-5074
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 65
- States / cities
- Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
- Drug
- Lead sponsor
- vTv Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 59
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Escondido, California + 52 more
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Interventions
- Evolocumab, Routine Lipid Management
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,019 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
- Conditions
- Colorectal Cancer
- Interventions
- Decision aid and navigation
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Albuquerque, New Mexico • Chapel Hill, North Carolina • Charlotte, North Carolina
- Conditions
- Primary Systemic (AL) Amyloidosis
- Interventions
- NEOD001, Placebo
- Drug · Other
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
- Conditions
- HIV Infection
- Interventions
- Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 94
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Vildagliptin, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 141
- States / cities
- Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more
- Conditions
- Ovarian Cancer
- Interventions
- oregovomab
- Drug
- Lead sponsor
- Unither Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 62
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Endometriosis
- Interventions
- Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
- Conditions
- Ankle (Ligaments); Instability (Old Injury)
- Interventions
- Balance Training, STARS
- Behavioral
- Lead sponsor
- University of North Carolina, Charlotte
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
- Procedure · Other · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 117 more
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Interventions
- Pasritamig, Placebo, Best Supportive Care (BSC)
- Biological · Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 53
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 42 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aricept
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • El Centro, California • Los Angeles, California + 27 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 84
- States / cities
- Little Rock, Arkansas • Baldwin Park, California • Beverly Hills, California + 67 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- motavizumab (MEDI-524), palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 6,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 120
- States / cities
- Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Interventions
- Dihydroergotamine, Placebo
- Drug
- Lead sponsor
- Satsuma Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 127
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 106 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
- Conditions
- Osteoarthritis
- Interventions
- tanezumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 226
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more